Discovery that VIP receptor VIPR2 must dimerize to bind vasoactive intestinal peptide reveals fundamental receptor biology with implications for VIP-based drug design.
Key findingDiscovery that VIP receptor VIPR2 must dimerize to bind vasoactive intestinal peptide reveals fundam
What the researchers found
Discovery that VIP receptor VIPR2 must dimerize to bind vasoactive intestinal peptide reveals fundamental receptor biology with implications for VIP-based drug design.
Why it matters
Relevant to peptide therapeutics.
How the study worked
In publication.
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Dimerisation of the VIP receptor VIPR2 is essential to its binding VIP and Gαi proteins, and to its functions in breast cancer cells.
British journal of pharmacology, 182(15), 3612-3627
Citation
Asano, Satoshi; Ozasa, Kairi; Uehara, Teru; Yokoyama, Rei; Nakazawa, Takanobu; Yanamoto, Souichi; Ago, Yukio. (2025). Dimerisation of the VIP receptor VIPR2 is essential to its binding VIP and Gαi proteins, and to its functions in breast cancer cells.. British journal of pharmacology, 182(15), 3612-3627. https://doi.org/10.1111/bph.70039